International Specialist Educates local Healthcare Practitioners on Cardiovascular Disease |
|
Dubai - Heads of Departments, key medical practitioners and pharmacists from across the UAE recently attended three symposiums in Dubai and Abu Dhabi on the impact of Atenolol in cardiovascular disease.
The organizer of the three events, Globalpharma, a subsidiary of Dubai Investments PJSC, invited internationally renowned specialist, Dr. Enrico Balli, M.D. from the Coronary Care Unit at Della Robbia Hospital in Italy to share his knowledge and expertise with local healthcare professionals.
Atenolol is used alone or in combination with other medications to treat high blood pressure. It also is used to prevent angina (chest pain) and treat heart attacks. Atenolol is in a class of medications called beta blockers. It works by slowing the heart rate and relaxing the blood vessels so the heart does not have to pump as hard.
Dr. Balli's presentation included information on the clinical application of Atenolol in patients with conditions such as hypertension, angina and myocardial infarction (heart attack).
Dr. Balli says, "I am delighted to have been presented with the opportunity to share best practice with colleagues in the Middle East. The treatment of cardiovascular disease continues to present significant challenges to healthcare practitioners across the globe. Continued education is essential to maintain and whenever possible, improve standards of care."
Dr. Maged Amer, Acting General Manager, Globalpharma adds, "The knowledge of an internationally renowned specialist such as Dr. Balli is invaluable for the continuing development of healthcare in the UAE. Globalpharma is proud to support the education of local UAE based practitioners, which we hope, will ultimately provide better cardiac care for patients."
- Ends -About Globalpharma
Globalpharma is a modern pharmaceutical manufacturing unit committed to offering international quality pharmaceutical products to the Middle East as well as global markets.
The Globalpharma site is built on a plot measuring approximately 27000 square meters in Dubai Investment Park, about 50 kms from the city centre. The factory has two separate manufacturing units, for Penicillin and Non-Penicillin products, with the utilities in a separate block. The manufacturing facility is capable of producing a wide range of products, in several dosage forms including tablets, capsules and dry syrups in the Penicillin block as well as tablets, capsules, liquid oral syrups and suspensions in the Non-Penicillin block.
Designed to meet international standards of cGMP, including those of G.C.C Ministries of Health, US Food and Drugs Administration (F.D.A) and UK Medicines Control Agency (MCA), the manufacturing facilities are equipped and staffed with strict adherence to the highest quality standards across every process.
© Press Release 2005
Zawya is a distributor (and not a publisher) of content supplied by third parties and subscribers. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by those third parties, including information providers, subscribers or other users of the Service, are those of the respective author(s) or distributor(s) and not of the Company. The Company neither endorses nor is responsible for the accuracy or reliability of any opinion, advice or statement made on the Service by anyone other than authorized Service employee spokespersons while acting in their official capacities. The Company is not responsible for any infringement of intellectual property rights or breach of any applicable law or regulation, including regulation in relation to financial services or the distribution of financial products, defamation, data protection, telecommunications (including regulations relating to excessive use, spamming or other abusive activities) or obscene, offensive or illegal content). Under no circumstances will the Company be liable for any loss or damage caused by a member's reliance on information obtained through the Service. It is the responsibility of member to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content available through the Service. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific information, opinion, advice or other content.
Read the full Member Agreement
http://www.zawya.com/legal/NewsLetter.cfm?name=disclaimer
Comment on this article 
Loading ...-
Zawya encourages you to add a comment to this discussion. You agree that when you add content to this discussion your comments will not:
1.1 Contain any material which is libelous or defamatory of any person, is obscene, offensive, hateful or inflammatory or causes damage to the reputation of any person or organisation.
1.2 Promote sexually explicit material, violence, discrimination based on race, sex, religion, nationality, disability, sexual orientation or age or any illegal activity.
1.3 Be made in breach of any legal duty owed to a third party, such as a contractual duty or a duty of confidence.
1.4 Be threatening, abuse or invade another's privacy, or cause annoyance, inconvenience or needless anxiety.
1.5 Be used to impersonate any person, to misrepresent your identity or affiliation with any person, or be likely to deceive any person.
1.6 Give the impression that they represent Zawya.
1.7 Advocate, promote or assist any unlawful act such as (by way of example only) copyright infringement or computer misuse. - The content posted on www.zawya.com is created by members of the public. The views expressed are theirs and unless specifically stated are not those of Zawya. Zawya reserves the right to review all comments prior to posting and edit or delete any contribution, but Zawya is not responsible for and can not be held liable for any content posted by members of the public on www.zawya.com.
- Zawya is not responsible for the availability or content of any third party sites that are accessible through www.zawya.com. Any links to third party websites from www.zawya.com do not amount to any endorsement of that site by Zawya and any use of that site by you is at your own risk.
- By submitting your comment, you hereby give Zawya the right, but not the obligation, to post, air, edit, exhibit, telecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comments worldwide, in perpetuity.
Stories
Companies
| Company Name | Country | Industry |
| Consolidated Contractors Company | Overseas | Construction and Design |
| Saudi Binladin Group | Saudi Arabia | Construction and Design |
| Saudi Telecom | Saudi Arabia | Telecommunications Services |
| Saudi Electricity Company | Saudi Arabia | Electric Utilities |
| Qatar Engineering and Construction Company | Qatar | Construction and Design |
| Ministry of Health - Saudi Arabia | Saudi Arabia | Ministries and Municipalities |
| Zuhair Fayez Partnership Consultants | Saudi Arabia | Construction and Design |
| Nissan Motor Egypt | Egypt | Transportation Products |
| Ministry of Health - Kuwait | Kuwait | Ministries and Municipalities |
| Hyundai Engineering and Construction Company - Saudi Arabia | Saudi Arabia | Construction and Design |
Projects
| Project Name | Country | Sector |
| ADNOC/ConocoPhillips - Sour Gas Fields Development - Shah Field | UAE | Oil and Gas |
| ENEC - Nuclear Power Plant | UAE | Power and Water |
| Takreer - Ruwais Refinery Expansion | UAE | Oil and Gas |
| SATORP - Jubail Refinery and Petrochemical Complex | Saudi Arabia | Oil and Gas |
| Aramco/Dow Chemical - Ras Tanura Integrated Refinery and Petrochemicals Complex | Saudi Arabia | Oil and Gas |
| Abu Dhabi Ports Company - Khalifa Port and Industrial Zone (KPIZ) | UAE | Infrastructure |
| IGD - Gasco - Habshan 5 Gas Processing Plant | UAE | Oil and Gas |
| Qatar Foundation - Sidra Medical and Research Center | Qatar | Real Estate |
| Emirates Aluminium (EMAL) - Smelter Complex - Phase 1 | UAE | Industry |
| Abu Dhabi DOT - Abu Dhabi Metro | UAE | Infrastructure |
Blogs
|
||||||||||||||||||||||||||||||||||
